Esflurbiprofen transdermal - Teikoku Seiyaku

Drug Profile

Esflurbiprofen transdermal - Teikoku Seiyaku

Latest Information Update: 16 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Teikoku Seiyaku
  • Class Analgesics; Nonsteroidal anti-inflammatories; Propionic acids
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Acute pain

Most Recent Events

  • 15 Apr 2016 Clinical trials in Acute pain in USA (Topical) prior to April 2016
  • 15 Apr 2016 Teikoku Seiyaku plans a phase II trial for Acute pain in USA (NCT02729207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top